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13 Thrombosis and Thrombin
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Department of Biochemistry, University of Limburg, The Netherlands and
Department of Hematology CHU Necker-Enfants Malades, Paris, France
Introduction
One of the most interesting properties of thrombosis is that it seems to be caused
by the hobby of each particular author. You may thus have seen thrombosis
attributed to psychosociological behaviour, feeding habits, unbalanced prostanoid
metabolism, lack of certain plasma proteins, excess of other plasma proteins,
platelet properties, physical activity and what not . . It will not come as a
surprise, therefore, that we defend the position that thrombosis is caused by
thrombin generation. Before doing so, it might be safe to explain that we do not
think that any of the so-called causes of thrombosis has the exclusive right of
way. The majority of them are not mutually exclusive but rather mark sequential
or parallel steps in a still poorly understood sequence of events. The point that
we should like to make here is that all the problems around thrombosis finally
pivot on one single hinge and that this hinge is thrombin generation.
Thrombin
If thrombin generation is not the unique cause of thrombosis, it is the firnl common
path of all causes of thrombosis. This becomes quite obvious if one uses a yard-
stick that must be recognized by basic scientists, theoreticians and clinicians alike;
that is therapeutic success. They would probably agree that, if we list the successful
therapies against thrombosis and if we can then find a common denominator, this
common denominator is likely to point to a key mechanism in thrombosis.
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Anti-thrombotic Agents
At this moment there are only two drugs that are universally recognized as efficient
antithrombotics: vitamin K antagonists and heparins.
Anti-vitamin K therapy
Let us consider oral anticoagulants first. Their use in preventing venous throm-
bosis is unchallenged at the present time. In arterial thrombosis it has taken longer
for the item to be settled. After the trial published in 1980 by the Leyden group
I feel that we can accept that oral anticoagulation can prevent coronary reinfarction
and it does not take us too far to extend this conclusion to all arterial thrombosis
(de Vries et al., 1980). The more so, as from the same study a positive effect
of anti-vitamin K treatment on cerebral arterial thrombosis can be concluded.
These results are no longer annihilated by the negative results of other trials,
because Loeliger was able to show that unsuccessful trials are unsuccessful always
and only if the level of anticoagulation that is obtained is not continuous and of
a suitable low level. We therefore at this moment can safely accept that prolonged
treatment with a high enough dose of a vitamin K antagonist has an antithrombotic
effect (Loeliger. 1984).
Now what does a vitamin K antagonist do to a patient? Recent research, notably
from the group of Vermeer in our laboratory, has shown that there are many
vitamin K dependent proteins in the body. Kidney, bone, testis, vessel wall and
liver all produce such proteins (Vermeer and de Boer van den Berg, 1985). The
clotting factors II, V[, IX and X and the anti-clotting factors C and S are only
a small subgroup among them. Yet patients that have been subjected to an oral
anticoagulant treatment for many years have never been reported to show effects
other than a tendency to bleed and, strictly in parallel, a tendency not to develop
thrombosis. This makes it unlikely that the main effect of these drugs should be
anything other than on the haemostatic mechanism in blood or on the arterial wall.
Heparin
Let us now turn our attention to heparin. Here the situation looks hopelessly
complicated because heparin is an uncanny mixture of a large number of different
substances while each of them may have several different actions (Henker et al.,
1986a). As you know, heparin can interact with antithrombin III (AT III) to form
a complex that can inactivate all proteases of the coagulation cascade. Heparin
also interacts directly with thrombin and so can inhibit several important feed-
back activations, independently from AT III. This means that, in coagulation only,
at least seven different reactions exist that are possible targets for heparin action.
On the other hand, it has been found that lipid-bound coagulation enzymes'
especially when accompanied by their protein cofactor, are less sensitive to the
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is possible to obtain the prothrombinase curve from the thrombin generation curve
by a calculation based upon the differential equations that describe the chemical
system. This calculation can be carried out with the aid of a computer. This
instrument thus acts as a kind of enzyme kinetic microscope that shows us details
in our experimental material that are not immediately apparent to the naked eye
(Hemker et al., 1986b).
We measured thrombin generation in the presence and in the absence of heparin,
and of course reafftrmed the much smaller thrombin generation in the presence
of heparin. When we then calculated the velocity of prothrombin conversion' we
expected to find it had also decreased due to the factor Xa and/or factor IXa
inactivation induced by the heparin. To our great surprise, however, the pro-
thrombinase activity as induced by diluted thromboplastin appeared not to be
inhibited. The intrinsic coagulation pathway on the other hand was inhibited, but
this inhibition vanished as soon as factor VIII was preactivated before coagulation
was started. This indicated that again inhibition of thrombin forms the basis of
the action of heparin, i.e. that in the intrinsic system it expresses itself via the
non-activation of factor VIII.
We must conclude that in clotting plasma all three of the factors VIIa'
IXa and Xa are completely insensitive to inactivation by AT Ill-heparin and
that classical unfractionated heparin acts mainly on thrombin (B6guin and
Hemker, 1987). The common denominator of the effect of oral anticoagulation
and of heparin in platelet-poor plasma seems to be thrombin and nothing
but thrombin.
of course, platelet-poor plasma is only a small sub-system of the whole
organism. We would not like to claim that our results exclude the possibility of
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an action of anticoagulant herapy on the vessel wall, the platelet or elsewhere.
We feel, however, that we may exclude from the possible list of target reactions
those that have been shown not to be inhibited in the system that we studied,
i.e. all those leading to thrombin generation in platelet-poor plasma. It might also
be possible that vitamin K antagonists act by some mechanism not involving
thrombin, and heparins by another. For the moment, we feel this to be highly
unlikely and therefore we claim a pivotal role for thrombin in thrombosis
formation.
The next thing to do will be to extend our studies to the next larger sub-system,
i.e. platelet-rich plasma. We will meet some rather formidable technical problems
but they do not seem insurmountable.
At this moment one may recall Popper and say that, if we could produce an
example of an effective antithrombotic therapy that does not affect thrombin
generation, our thesis would be invalidated. There are two possible candidates:
frrst antiplatelet therapy and secondly low dose heparin therapy.
Zwaal (this volume) describes how small amounts of thrombin will transform
platelets that are sticking to collagen, into very powerful foci of thrombin
generation. It is thus quite possible that platelet inhibition will prevent thrombin
formation at the site of a wound. Conversely, because thrombin is a very potent
platelet activator, it is also possible that inhibition of thrombin generation is the
best possible way to inhibit platelets. Platelets and thrombin generation are anyhow
linked so closely that an antithrombotic effect of an antiplatelet drug cannot be
taken as counter evidence for the role of thrombin in thrombosis.
The case of low dose subcutaneous heparin may seem more challenging. Up
to this moment no significant antithrombin action of such therapy has been
demonstrated, whereas its antithrombotic properties appear from clinical trials
(Kakkar et al.,1982). However, we were recently able to show that subcutaneous
heparin administration does have an influence on thrombin generation. Basing
our approach on experiments from Professor Josso's laboratory we investigated
the activation of factor VIII in the blood emerging from a finger prick (Josso
et at.,1976).It has been demonstrated that this activation is the best indicator
of trace amounts of thrombin. Consequently inhibition of this activation of factor
VIII indicates inhibition of thrombin generation in the wound. If we follow factor
VIII activation from a capillary puncture after administration of 1,000 units of
classical heparin subcutaneously, we see that heparin activity can only be
demonstrated with difficulty by the APTT or other common laboratory tests' The
activation of factor VIII, however, is inhibited between 2 and 4 h after the injection.
Therefore this therapy inhibits thrombin formation (J. Fiolet and D. P' Devil6e,
personal communication) and its clinical success does not invalidate our conclusion.
Low molecular weight (LMW) heparins and heparinJike substances offer the
next challenge. Let us take pentosan polysulphate (PPS, Hemoclar@ ) as an example.
This drug has been shown to be an effective antithrombotic agent even if AT III
is absent. Recently Wagenvoord et al. (1986) from our laboratory, determined
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Perspectives
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Time
FIG. I N shows a norrnal thrombin generation curve, i.e. the development of thrombin in time
triggering of coagulation. As soon as it extends into area T, the thrombosis risk zone, even pr
with healthy vessels tend to thrombosis (e.g antithrombin III deficiency) With the increase of(and other risk factors) the boundary of the thrombosis danger zone shifts downwards (dotted li
Anticoagulant therapy can move the thrombin generation curve out of the danger /one (curve
Antrcoagulatron should not lead, however, to curves entering the bleeding risk zone @,.
potency of these substances. This will instruct us about the relation of the thrombi
generation curve and bleeding or thrcmbosis. In this way the coagulation
together with the medical research profession and pharmaceutical industry
hope to define the ideal anticoagulant.
Summary
All effrcient antithrombotic therapeutic agents cause a decrease in thrombin
tion in the blood of the patient. Thrombin therefore is very probably crucial
the final common path in the pathogenesis of thrombosis. on the other hand,
is also the key enzyme of haemostasis. Yet the time course of thrombin
Ieading to haemostasis and to thrombosis is different. It must therefore be
to obtain a non-haemorrhagic antithrombotic drug by specific inhibition of certain
steps in the reactions that determine this time course.
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Discussion
Dr Coller: Could Dr Hemker comment on the perplexing role of factor XI?
Dr Hemker: I can comment on it, but I cannot say anything sensible about it. In 100
patients lacking factor XI there may be five who indeed have a serious bleeding tendency.
I cannot explain why they have that, or why the other 95 patients do not.
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Dr Zwaalz Dr Hemker will of course know that if a small amount of thrombin is added
to an animal, that does not lead to a thrombotic state but rather to a bleeding state. This
has recently been explained by the fact that thrombin is carried away by thrombomodulin.
Is it known whether there is any thrombomodulin on the venous endothelial cell?
Dr Hemker: I think there is - but if thrombin is injected, there is a situation that is
much more akin to disseminated intravascular coagulation than to local haemostasis. This
isbecausethereisimmediatemixingof thethrombinwiththebulkof theblood. Of couise,
it is well known that in disseminated intravascular coaeulation the end effect is an
anticoagulation
Dr Zwaal: Is factor VIII activation a sensitive parameter for the amount of thrombin?
Dr Hemker: That is what is seen in disseminated intravascular coagulation. Factor VItr
is activated, but this factor is highly unstable in the circulation, so its level drops in these
cases as do the factor V and the platelet count.
Dr Sultan: With regard to the activation of factor VIII in the capillaries, Dr Hemker
showed that it can be increased by 25%?
Dr Hemker: No, that is not correct. We cannot convert the clotting time to the amount
of factor VIII, because after its activation, it becomes another molecular species; that is
the reason why I express roughly its activation by taking the difference between the long
time that is found in the first drop and the short time in the second drop divided by the
time in the first drop. It is completely arbitrary, but I know of no other way to express it.
Dr Sultan: So the reduction is from 25% to 5% when a low dose of heparin is given?
Dr Hernker: Yes, something like that, between 2 and 4 hours after injection.
Dr Caen: ' When some 20 years ago, we studied a patient with congenital hypo-
fibrinogenaemia with developed thrombosis, we looked at the thrombin generation test.
As expected, not only was it normal, but more than normal. At that time, we used a small
dose of heparin to cure that kind of thrombosis in congenital hypofibrinogenaemia, I would
consider that fibrinogen has no importance in that regard, but that thrombin generation
is quite important, as Dr Hemker stressed.
Dr Nurden: I think that Dr Hemker has made an important contribution to the meeting
because he has made us look away from the platelets towards the whole system that may
be responsible for thrombus formation.
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